ArticleScientific reports2017
Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Hydrogels in cancer treatment: mapping the future of precision drug delivery.Frontiers in immunology · 2025Pooled it
- Application of nanoparticles in breast cancer treatment: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- From LNPs to hybrid nanocarriers: development, challenges and redesign of non-viral gene delivery.Journal of nanobiotechnology · 2026Review
- Engineering Multimodal Nanomaterials for Prostate Cancer Theranostics: Design Principles, Recent Advances, and Translational Challenges.International journal of nanomedicine · 2026Review
- Novel Strategies for Precision Diagnosis and Treatment of Prostate Cancer Based on Multifunctional Nanocarrier Systems.International journal of nanomedicine · 2026Review
- Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside.Molecular cancer · 2025Review
- Oral Bioavailability Enhancement of Anti-Cancer Drugs Through Lipid Polymer Hybrid Nanoparticles.Pharmaceutics · 2025Review
- The Blood-prostate Barrier: An Obstacle to Drug Delivery into the Prostate.Current drug delivery · 2025Review
- Insight into the Recent Developments of Nanoparticles in Treatment of Cancer and Neuro-Degenerative Disease: A Review.Current topics in medicinal chemistry · 2025Review
- Overcoming cancer drug resistance: insights into Apoptotic pathway modulation by plant-based nanoparticle and natural products.Frontiers in oncology · 2025Review
- Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics.Molecular cancer · 2023Review
- Nanodelivery systems: An efficient and target-specific approach for drug-resistant cancers.Cancer medicine · 2023Review
- Lipid-Polymer Hybrid Nanosystems: A Rational Fusion for Advanced Therapeutic Delivery.Journal of functional biomaterials · 2023Review
- Core Shell Lipid-Polymer Hybrid Nanoparticles for Oral Bioavailability Enhancement of Ibrutinib via Lymphatic Uptake.AAPS PharmSciTech · 2023Article
- Targeting Sphingosine 1-Phosphate Metabolism as a Therapeutic Avenue for Prostate Cancer.Cancers · 2023Review
- Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy.Frontiers in immunology · 2023Review
- Recent Trends and Developments in Multifunctional Nanoparticles for Cancer Theranostics.Molecules (Basel, Switzerland) · 2022Review
- Nanocarrier cancer therapeutics with functional stimuli-responsive mechanisms.Journal of nanobiotechnology · 2022Review
- A spotlight on alkaloid nanoformulations for the treatment of lung cancer.Frontiers in oncology · 2022Review
- Chemopreventive Potential of Dietary Nanonutraceuticals for Prostate Cancer: An Extensive Review.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many prostate cancers relapse after initial chemotherapy treatment. Combining molecular and chemotherapy together with encapsulation of drugs in nanocarriers provides effective drug delivery and toxicity reduction. We developed core shell lipid-polymer hybrid nanoparticles (CSLPHNPs) with poly (lactic-co-glycolic acid) (PLGA) core and lipid layer containing docetaxel and clinically used inhibitor of sphingosine kinase 1 (SK1) FTY720 (fingolimod). We show for the first time that FTY720 (both free and in CSLPHNPs) re-sensitizes castrate resistant prostate cancer cells and tumors to docetaxel, allowing a four-fold reduction in effective dose. Our CSLPHNPs showed high serum stability and a long shelf life. CSLPHNPs demonstrated a steady uptake by tumor cells, sustained intracellular drug release and in vitro efficacy superior to free therapies. In a mouse model of human prostate cancer, CSLPHNPs showed excellent tumor targeting and significantly lower side effects compared to free drugs, importantly, reversing lymphopenia induced by FTY720. Overall, we demonstrate that nanoparticle encapsulation can improve targeting, provide low off-target toxicity and most importantly reduce FTY720-induced lymphopenia, suggesting its potential use in clinical cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.